featured
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With MRD Response–Adapted Therapy in Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
J. Clin. Oncol 2021 Dec 13;[EPub Ahead of Print], LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, R Silbermann, B Dhakal, S Bal, S Giri, A D'Souza, A Hall, P Hardwick, J Omel, RF Cornell, P Hari, NS CallanderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.